Author + information
- Received July 10, 2017
- Revision received November 6, 2017
- Accepted November 11, 2017
- Published online February 26, 2018.
- Jonathan D.W. Evans, MBChBa,b,
- Stephen J.H. Dobbin, MBChBc,
- Stephen J. Pettit, PhDb,
- Emanuele Di Angelantonio, PhDa,d,e and
- Peter Willeit, PhDa,f,∗ ()
- aDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
- bTransplant Unit, Papworth Hospitals NHS Foundation Trust, Papworth Everard, Cambridge, United Kingdom
- cDepartment of Cardiology, Golden Jubilee National Hospital, Clydebank, Glasgow, United Kingdom
- dNIHR Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, United Kingdom
- eNHS Blood and Transplant, Cambridge, United Kingdom
- fDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria
- ↵∗Address for correspondence:
Dr. Peter Willeit, Medical University of Innsbruck, Department of Neurology, Anichstrasse 35, 6020 Innsbruck, Austria.
Objectives The aim of this study was to systematically collate and appraise the available evidence regarding the association between high-sensitivity cardiac troponin (hs-cTn) and incident heart failure (HF) and the added value of hs-cTn in HF prediction.
Background Identification of subjects at high risk for HF and early risk factor modification with medications such as angiotensin-converting enzyme inhibitors may delay the onset of HF. Hs-cTn has been suggested as a prognostic marker for the incidence of first-ever HF in asymptomatic subjects.
Methods PubMed, Embase, and Web of Science were systematically searched for prospective cohort studies published before January 2017 that reported associations between hs-cTn and incident HF in subjects without baseline HF. Study-specific multivariate-adjusted hazard ratios (HRs) were pooled using random-effects meta-analysis.
Results Data were collated from 16 studies with a total of 67,063 subjects and 4,165 incident HF events. The average age was 57 years, and 47% were women. Study quality was high (Newcastle-Ottawa score 8.2 of 9). In a comparison of participants in the top third with those in the bottom third of baseline values of hs-cTn, the pooled multivariate-adjusted HR for incident HF was 2.09 (95% confidence interval [CI]: 1.76 to 2.48; p < 0.001). Between-study heterogeneity was high, with an I2 value of 80%. HRs were similar in men and women (2.29 [95% CI: 1.64 to 3.21] vs. 2.18 [95% CI: 1.68 to 2.81]) and for hs-cTnI and hs-cTnT (2.09 [95% CI: 1.53 to 2.85] vs. 2.11 [95% CI: 1.69 to 2.63]) and across other study-level characteristics. Further adjustment for B-type natriuretic peptide yielded a similar HR of 2.08 (95% CI: 1.64 to 2.65). Assay of hs-cTn in addition to conventional risk factors provided improvements in the C index of 1% to 3%.
Conclusions Available prospective studies indicate a strong association of hs-cTn with the risk of first-ever HF and significant improvements in HF prediction.
Dr. Evans is supported by a clinical research fellowship from the British Heart Foundation Cambridge Centre of Research Excellence. Dr. Willeit was supported by the excellence initiative (Competence Centers for Excellent Technologies) of the Austrian Research Promotion Agency FFG: Research Center of Excellence in Vascular Ageing – Tyrol, VASCage (K-Project 843536), funded by Bundesministerium für Verkehr, Innovation und Technologie, Bundesministerium für Wissenschaft, Forschung und Wirtschaft, Wirtschaftsagentur Wien, and Standortagentur Tirol. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received July 10, 2017.
- Revision received November 6, 2017.
- Accepted November 11, 2017.
- 2018 American College of Cardiology Foundation